Heron Therapeutics Inc (NAS:HRTX)
$ 3.57 0.26 (7.85%) Market Cap: 537.83 Mil Enterprise Value: 607.06 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 66/100

Heron Therapeutics Inc to Host U.S. FDA Approval of ZYNRELEF™ - Conference Call Transcript

May 13, 2021 / 12:30PM GMT
Release Date Price: $15.54 (-10.77%)
Operator

Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Heron Therapeutics conference call to discuss the FDA approval of ZYNRELEF. As a reminder, this conference is being recorded. Now I would like to turn over the call to David Szekeres, Executive Vice President, Chief Operating Officer. Sir, please go ahead.

David L. Szekeres
Heron Therapeutics, Inc. - Executive VP & COO

Thank you, Ural. Good afternoon, everyone, and thank you for joining us. With me today from Heron are Barry Quart, Chief Executive Officer and Chairman; John Poyhonen, President and Chief Commercial Officer; Kimberly Manhard, Executive Vice President, Drug Development and Board Director; Chris Storgard, Chief Medical Officer; and Mike Mathews, Senior Vice President, Acute Care franchise.

For those of you participating via conference call, the slides are made available via webcast and can also be accessed by going to the Investor Relations page of our website.

Barry will provide introductory remarks and offer context around the FDA approval of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot